Christy Kim, Ph.D. Email & Phone Number

Waltham, Ma, Us

• Responsible for developing, implementing, and actively leading global market development plans for comprehensive genomic profiling (CGP) in oncology for solid tumors• Develop annual strategic and tactical marketing plans that are aligned with internal and external partners while updating plans based on new opportunities and channel feedback• Develop positioning, messaging, collateral, and training to educate the salesforce to be able to competitively position our products within the crowded next-generation sequencing (NGS) market• Continuously monitor competitors to highlight threats, opportunities, and potential market shifts while developing competitive response strategies to effectively counter the competition• Manage and cultivate external partnerships with collaborators and speakers to drive peer-to-peer education on the value of CGP for pathologists and oncologists

Santa Clara, Ca, Us

• Build innovative marketing programs and campaigns to build brand awareness and product education for the launch of Resolution ctDx FIRST, a liquid biopsy companion diagnostic for Mirati Therapeutics’ KRAZATI • Collaborate with internal and external stakeholders to develop product messaging, promotion, and commercialization plans directed towards medical oncologists and biopharma partners• Manage agency of record to deliver effective product marketing collateral and facilitate promotional review both internally with medical, legal, and regulatory and externally with our channel and biopharma partners• Competitive intelligence analysis to support product value proposition and new product development to guide optimal business decisions and to stay competitive within the precision medicine landscape• Worked cross-functionally to create clinical evidence dossiers, medical affair presentations, and MSL training materials to support the reimbursement and adoption of NGS

Austin, Texas, Us

• Championed and promoted a circulating tumor DNA (ctDNA) molecular residual disease (MRD) detection assay (Signatera) by creating marketing collateral targeting surgical oncologists and medical oncologists specializing in colorectal cancer (CRC) and immuno-oncology (IO) applications• Managed the promotional speaker bureau (over 200 speaking engagements in 1 year) and created speaker decks (branded/unbranded) to facilitate peer-to-peer education on the clinical utility of MRD detection to help inform treatment decisions with insights from key opinion leaders (KOLs)• Analyzed ongoing clinical and competitor data with scientific and medical affairs to support marketing claims and competitor positioning for the sales team• Supported the development and execution of the Signatera value proposition, customer positioning, and the end-to-end customer experience by getting insights from advisory boards and interviewing KOLs

Palo Alto, Ca, Us

• Executed rebranding of Boston Scientific’s acquired microspheres product family (Embozene, Oncozene, Tandem) marketing collateral to comply with Varian’s branding and promotional review committee • Developed global sales brochures, product sales presentations, technical guides, pocket references, talk-tracks, and clinical evaluation forms as initiatives to empower the sales team and gather market intelligence• Implemented a regulated content management platform (SoloFire) for regional specific distribution of marketing collateral, sales training, and clinical education material• Provided technical and clinical on-label support to the field and off-label support to the medical affairs team in disease states including hypervascular tumors, arteriovenous malformations, hepatocellular carcinoma (HCC), metastatic colorectal cancer (mCRC), uterine fibroids, benign prostate hyperplasia, and new therapeutic indications• Developed strategic marketing plans for the bland and drug-eluting microspheres by segmenting the addressable market and formulating tactical plans to increase procedural volume and competitive takeaways

Hayward, Ca, Us

• Executed scientific development through preclinical studies in animal and human models and clinical studies in veterinary medicine (canine oral melanoma) to advance the Nano-Pulse Stimulation (NPS) technology into immuno-oncology applications• Analyzed preclinical and clinical data to optimize combination strategies that included toll-like receptor agonists and checkpoint inhibitors to potentiate the immune response associated with antigenic release• Researched and proposed potential applications of the NPS technology based on its unique mechanism of action- immunogenic cell death, the pathophysiology of relevant disease states, and the market potential• Collaborated with R&D, preclinical sites, and research institutions to test feasibility of new applications

Latham, New York, Us

• Initiated preclinical development for the Oncology/Surgery Global Business Unit (GBU) to establish safety and feasibility in entering strategic markets to expand the ablation technology portfolio especially in immuno-oncology and combination therapies targeting cancer biology with irreversible electroporation (NanoKnife)• Collaborated with R&D, KOLs, and preclinical sites to test feasibility for new product development• Developed global markets for the product family through marketing programs, disease state awareness, clinical data generation, healthcare economics focus, and proper messaging and positioning

Latham, New York, Us

• Developed and executed a global brand strategy to build brand equity for the Oncology/Surgery Global Business Unit• Launched the Solero Microwave Tissue Ablation (MTA) System through brand development, product launch support, sales training, trade shows, and digital marketing• Created sales education/training presentations to address HCP concerns and technical issues

Rancho Cordova, California, Us

• Developed and validated clinical stem cell applications and their associated protocols for good manufacturing practice (GMP) cellular manufacturing for CAR T-cellular therapies• Designed and executed customer specific protocols to optimize and commercialize cellular processing systems, microbubble assisted cell sorting technologies, and automated cell washing/thawing systems • Trained customers, supported customer evaluations, and generated supporting literature for all product lines including user manuals and application notes

Rancho Cordova, California, Us

• Developed new products and improved existing product lines, researched and analyzed market conditions identifying key competition, consumer trends, market requirements, and opportunities• Managed products lines, created product literature, managed beta and pilot studies, supported customers, and maintained key customer relationships and satisfaction• Executed product marketing plans and campaigns to generate product awareness and demand and supported sales with necessary product knowledge and technical expertise

Rancho Cordova, California, Us

• Designed, executed, and validated protocols for cord blood stem cell processing and bioarchiving

Davis, California, Us

• Developed a novel in vitro protocol and investigated the molecular mechanisms for directed differentiation of human embryonic stem cells into definitive endoderm by modulating Wnt/β-catenin and FGF signaling• Analyzed gene expression and promoter activity using Illumina NGS platform, real-time PCR, chromatin immunoprecipitation, and promoter-activated luciferase assays

Davis, California, Us

• Investigated the transcriptional regulation of human β-defensin 2 by IL-17A in airway epithelium

Ph.D., Biochemistry And Molecular Biology

B.S. With Honors, Biochemistry And Molecular Biology

Medical Marketing Program